PFE: Raised 2026 guidance as launched-product growth offsets key product declines and LOE pressure

What happened

Pfizer reported third-quarter revenue of $16.6 billion and adjusted diluted earnings per share of $0.87. It raised its full-year revenue and adjusted earnings guidance, saying growth from non-COVID products it launched or acquired helped offset declines in key products and pressure from upcoming loss of exclusivity and competition.

Confirmed

Global impact / market context

Higher guidance suggests Pfizer expects product growth to more than counter current declines over the year. But upcoming loss of exclusivity, when legal protection ends and rivals can compete, may reduce sales of key products, making continued growth from newer products important to revenue and earnings.

Analyst inference

The update presents two competing forces for Pfizer: launched or acquired products are supporting growth, while declines in key products, future loss of exclusivity, and competition weigh on the outlook. Investors may focus on whether newer products can sustain revenue as those pressures build.

Analyst inference

What to watch

1. Check Pfizer’s next reported revenue and adjusted earnings against the raised full-year guidance to see whether growth continues to offset declines in key products. Analyst inference
2. Watch for further details on which launched or acquired products are driving non-COVID growth, since the article does not identify their individual sales contributions. Analyst inference
3. Track updates on upcoming loss of exclusivity and competition, which could make key products more vulnerable to rival sales and add pressure to revenue. Confirmed

Evidence

• Original source link unavailable